Skip to content
My WebMD Sign In, Sign Up
Font Size

Metformin May Lower Risk of Prostate Cancer Death

Diabetic men using the drug had higher survival rates in cancer study

WebMD News from HealthDay

By Kathleen Doheny

HealthDay Reporter

MONDAY, Aug. 5 (HealthDay News) -- Metformin, a widely used diabetes drug, may reduce the risk of dying from prostate cancer, according to new research.

A study of nearly 4,000 diabetic men found that those taking metformin when diagnosed with prostate cancer were less likely to die of the cancer or other causes compared to men using other diabetes drugs.

"We demonstrated that metformin is associated with improved survival among diabetic patients with prostate cancer," said Dr. David Margel, a uro-oncologist at Rabin Medical Center in Petah Tikva, Israel, who conducted the research while at the University of Toronto.

"It's associated in a dose-response manner," he said. "The longer you were on metformin, the less likely you were to die of prostate cancer and of all causes."

But whether metformin can prevent prostate cancer progression in people without diabetes remains to be seen, experts say.

Diabetes and prostate cancer are common in the United States. This year, about 239,000 new cases of prostate cancer will be diagnosed, and more than 29,000 men will die from it, according to the American Cancer Society.

Type 2 diabetes is rampant, and metformin is the drug most commonly prescribed to treat it. More than 61 million metformin prescriptions were filled in the United States last year. Brand names include Glucophage and Glumetza. The drug, in its generic forms and certain brand names, is relatively inexpensive.

Previous research has focused on whether metformin might reduce the risk of getting prostate cancer, but most studies were negative. Some experts believe the drug instead works to improve survival once the cancer occurs.

In the new study, published online Aug. 5 in the Journal of Clinical Oncology, Margel looked at more than 3,800 diabetic men aged 67 or older who lived in Ontario. About one-third were taking metformin at the study's start. Others were using different diabetes drugs.

The men took the metformin for a median of 19 months (half longer than that, half shorter) before the cancer was diagnosed and nearly nine months after.

During roughly four years of follow-up, Margel found those who took metformin had a 24 percent reduction in risk from prostate cancer death for every additional six months of use after their cancer diagnosis. The risk reduction of death from other causes was initially the same but declined over time.

In both instances, although an association was found between metformin and survival, a direct cause-and-effect relationship was not established.

No reduction in death risk was seen for patients taking any other diabetes drug.

Although other diabetes drugs work by increasing the body's insulin production, metformin is an "insulin sensitizer" that works by making the body more sensitive to the insulin already produced. Insulin is needed to move glucose into cells for energy.

Today on WebMD

Prostate Cancer Overview
SLIDESHOW
what is your cancer risk
HEALTH CHECK
 
woman speaking with doctor
VIDEO
Prostate Nerve Transplant
VIDEO
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Men Ignore
FEATURE
 
Prostate Enlarged
VIDEO
Picture Of The Prostate
ANATOMY
 
Prostate Cancer Quiz
QUIZ
screening tests for men
SLIDESHOW
 
Prostate Cancer Symptoms
VIDEO
Vitamin D
SLIDESHOW